[1] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity′s roles in cancer suppression and promotion[J]. Science, 2011, 331(624): 1565-1570. DOI: 10.1126/science.1203486.
[2] 张银粉, 周航. 肿瘤的免疫逃逸机制研究进展[J]. 免疫学杂志, 2011, 27(4): 346-349.
[3] 任艳鑫, 李晓江, 张丽娟, 等. TAP1、TAP2及HLAI在鼻咽癌中的表达及临床意义[J]. 西安交通大学学报: 医学版, 2014, 35(4): 527-532, 546.
[4] Chang CS, Chang JH, Hsu NC, et al. Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma[J]. BMC Cancer, 2007, 7: 88. DOI: 10.1186/14712407788.
[5] Ren SP, Wang L, Wang H, et al. Gene therapy for human nasopharyngeal carcinoma by adenovirusmediated transfer of human p53, GMCSF, and B71 genes in a mouse xenograft tumor model[J]. Cancer Biother Radiopharm, 2008, 23(5): 591-602. DOI: 10.1089/cbr.2007.0447.
[6] 郭莹, 赵颖海, 罗爱华, 等. 鼻咽癌细胞中Fas、FasL蛋白表达及意义[J]. 临床与实验病理学杂志, 2013, 29(8): 824-827. DOI: 10.3969/j.issn.10017399.2013.08.002.
[7] 周健, 陶磊. IL10在肿瘤中的作用[J]. 国际肿瘤学杂志, 2013, 40(3): 181-184. DOI: 10.3760/cma.j.issn.1673422X.2013.03.006.
[8] 任艳鑫, 李晓江, 喻博, 等. VIL10下调鼻咽癌细胞TAP1基因表达的研究[J]. 中国耳鼻咽喉头颈外科, 2012, 19(5): 255-257.
[9] Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGFβ targeted cancer therapy[J]. Int J Biol Sci, 2012, 8(7): 964-978. DOI: 10.7150/ijbs.4564.
[10] Hu S, Zhou G, Zhang L, et al. The effects of functional polymorphisms in the TGFβ1 gene on nasopharyngeal carcinoma susceptibility[J]. Otolaryngol Head Neck Surg, 2012, 146(4): 579-584. DOI: 10.1177/0194599811434890.
[11] Poh YW, Gan SY, Tan EL. Effects of IL6, IL10 and TGFβ on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells[J]. Exp Oncol, 2012, 34(2): 85-89.
[12] 莫立根, 罗元, 党阳, 等. TGFβ1、CD34和αSMA在鼻咽癌中的表达及其意义[J]. 现代肿瘤医学, 2015, 23(2): 185-188. DOI: 10.3969/j.issn.16724992.2015.02.11.
[13] Flies DB, Sandler BJ, Sznol M, et al. Blockade of the B7H1/PD1 pathway for cancer immunotherapy[J]. Yale J Biol Med, 2011, 84(4): 409-421.
[14] Chen BJ, Chapuy B, Ouyang J, et al. PDL1 expression is characteristic of a subset of aggressive Bcell lymphomas and virusassociated malignancies[J]. Clin Cancer Res, 2013, 19(13): 3462-3473. DOI: 10.1158/10780432.CCR130855.
[15] Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer[J]. Cancer Immunol Immunother, 2012, 61(8): 1327-1341. DOI: 10.1007/s0026201212936.
[16] Loos M, Hedderich DM, Friess H, et al. B7h3 and its role in antitumor immunity[J]. Clin Dev Immunol, 2010: 683875. DOI: 10.1155/2010/683875.
[17] He C, Qiao H, Jiang H, et al. The inhibitory role of b7h4 in antitumor immunity: association with cancer progression and survival[J]. Clin Dev Immunol, 2011: 695834. DOI: 10.1155/2011/695834.
[18] 郑大勇, 董少婷, 陈锦章, 等. B7H3和 B7H4在鼻咽癌组织中的表达及意义[J]. 实用癌症杂志, 2014, 29(6): 617-619. DOI: 10.3969/j.issn.10015930.2014.06.003.
[19] Liao Q, Zeng Z, Guo X, et al. LPLUNC1 suppresses IL6induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation[J]. Oncogene, 2014, 33(16): 2098-2109. DOI: 10.1038/onc.2013.161.
[20] Sun W, Liu DB, Li WW, et al. Interleukin6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP2 and MMP9[J]. Int J Oncol, 2014, 44(5): 1551-1560. DOI: 10.3892/ijo.2014.2323.
[21] 汪铁军, 谢中华, 郑元秀, 等. 初诊鼻咽癌患者外周血CD4+CD25+Foxp3+调节性T细胞的变化及与TGFβ1的相关性[J]. 放射免疫学杂志, 2013, 26(4): 474-476. DOI: 10.3969/j.issn.10089810.2013.04.047.
[22] 江志超, 唐发清, 田道法, 等. 中晚期鼻咽癌患者CD4+CD25+T调节细胞及相关调节因子水平的免疫病理意义[J]. 中国医师杂志, 2013, 15(6): 721-724. DOI: 10.3760/cma.j.issn.10081372.2013.06.001.
[23] Su Z, Sun Y, Zhu H, et al. Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis[J]. Immunol Res, 2014, 58(1): 118-124. DOI: 10.1007/s120260138483y.
[24] 黄继红, 昂杰, 牟忠林, 等. 鼻咽癌患者组织中Treg细胞和Th17细胞与TNM分期相关性研究[J]. 海南医学院学报, 2013, 19(10): 1375-1377.
[25] 江志超, 唐发清, 田道法, 等. 中晚期鼻咽癌患者CD4+CD25+T调节细胞和Th17细胞的免疫病理意义[J]. 肿瘤基础与临床, 2014, 27(2): 105-108. |